Cell & Gene Therapy CDMOs — Ranked by Signal Score · 2026

Last updated: 2026-10-06 · updated as new inspection, certificate, and trial data enters the platform

Best Clean FDA History Commercial Scale

Region: USA Europe Asia UK India Switzerland Germany South Korea Japan China

105

CDMOs tracked

105

Fully scored

With FDA records

108

FDA inspections

333

EMA/MHRA GMP certs

Warning letters

On CDMO Signal's composite Signal Score, Bristol Myers Squibb (CGT Mfg), Novartis, and City of Hope (T Cell Manufacturing) lead the cell and gene therapy CDMO rankings — an aggregation across cell therapy manufacturers (CAR-T, TCR, NK, stem cell) and viral vector manufacturers (AAV, lentiviral, adenoviral). The Signal Score is a 0–100 composite of four weighted pillars — Quality Compliance (35%), Operations (25%), Financial Stability (20%), and Capacity Intelligence (20%) — built from FDA inspection history, EMA/MHRA GMP certificates, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. Ex vivo cell therapy programs typically pair a lentiviral vector supplier with a cell processing CDMO; sponsors running combined scope often prefer integrated CDMOs to reduce tech transfer risk. For platform-filtered rankings see the dedicated cell therapy, AAV, and lentiviral pages. Full methodology at cdmosignal.com/methodology.

Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.

For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).

FDA inspection outcomes across these CDMOs: 48 NAI (no action), 55 VAI (voluntary action), 5 OAI (official action). Leading inspection & GMP sites: United States (89), UNITED KINGDOM (68), Austria (56), Germany (45), Denmark (35).

Last updated 2026-10-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	BMS Bristol Myers Squibb (CGT Mfg) Bothell, WA · Warren, NJ	91.1	97.9	6 insp · 2 GMP	—	585 programs
2	Novartis Basel, Switzerland	87.1	93.1	16 insp · 67 GMP	—	135 programs
3	COH City of Hope (T Cell Manufacturing) Duarte, CA	83.9	97.1	3 insp · 0 GMP	—	213 programs
4	TK Takeda Boston, MA · Zurich, CH	81.9	99.6	4 insp · 18 GMP	—	100 programs
5	MK Merck KGaA / MilliporeSigma (CDMO) Darmstadt, DE · St. Louis, MO	81.8	98.7	2 insp · 2 GMP	—	22 programs
6	TF Thermo Fisher Scientific Plainville, MA · Alachua, FL · Cambridge, MA	81.0	100.0	6 insp · 10 GMP	Available	2 programs
7	BY Bayer (Cell Therapy Mfg) Berkeley, CA	80.4	90.1	8 insp · 18 GMP	—	126 programs
8	CS Cedars-Sinai Biomanufacturing Los Angeles, CA	79.8	100.0	1 insp · 0 GMP	—	34 programs
9	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	78.6	100.0	2 insp · 23 GMP	Available	2 programs
10	OX Oxford Biomedica Oxford, United Kingdom	76.2	100.0	0 insp · 13 GMP	Available	7 programs
11	Lonza Basel, Switzerland	76.0	95.7	2 insp · 8 GMP	—	1 programs
12	CI Cincinnati Children's Vector Production Facility Cincinnati, OH	75.2	100.0	1 insp · 0 GMP	—	1 programs
13	NR National Resilience San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA	74.5	98.0	1 insp · 0 GMP	Available	9 programs
14	MB Miltenyi Biotec Bergisch Gladbach, Germany	73.0	100.0	0 insp · 2 GMP	—	8 programs
15	RT ReiThera Rome, IT	71.1	100.0	0 insp · 4 GMP	—	1 programs
16	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	90.9	98.3	8 insp · 11 GMP	Limited	0 programs
17	RP ReciBioPharm Keele, UK · Sodertalje, SE	88.0	100.0	0 insp · 3 GMP	—	0 programs
18	PB Pharmaron Biologics San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China	86.9	100.0	3 insp · 0 GMP	Available	0 programs
19	FD FUJIFILM Diosynth Biotechnologies Research Triangle, NC · Holly Springs, NC · Hillerod, DK	84.8	100.0	0 insp · 23 GMP	Expanding	0 programs
20	KB KBI Biopharma Durham, NC · Boulder, CO	84.4	99.1	1 insp · 1 GMP	Limited	0 programs
21	AJ Ajinomoto Bio-Pharma Services San Diego, CA · Osaka, JP	83.5	100.0	0 insp · 1 GMP	—	0 programs
22	MN Minaris Advanced Therapies Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP	83.3	99.6	1 insp · 6 GMP	Limited	0 programs
23	WB2 WuXi Biologics Shanghai, CN · Wuxi, CN	82.9	100.0	0 insp · 4 GMP	—	0 programs
24	LB Lotte Biologics Incheon, KR · Syracuse, NY	81.6	100.0	1 insp · 0 GMP	—	0 programs
25	SC SCTbio Prague, Czech Republic	81.6	100.0	0 insp · 5 GMP	—	0 programs
26	EF Eurofins CDMO Planegg, DE · San Diego, CA	81.6	100.0	5 insp · 0 GMP	—	0 programs
27	DH Danaher (CGT Portfolio) Washington, DC	81.5	—	—	—	0 programs
28	NW Northway Biotech Vilnius, LT; Waltham (MA), USA	80.8	100.0	0 insp · 8 GMP	Available	0 programs
29	RC RoslinCT Edinburgh, UK · Hopkinton, MA	80.3	99.0	1 insp · 1 GMP	Available	0 programs
30	CF CELLforCURE (SEQENS) Les Ulis, FR	80.3	100.0	0 insp · 4 GMP	—	0 programs
31	BR BioReliance (Merck) Glasgow, UK · Rockville, MD	80.2	97.1	4 insp · 8 GMP	—	0 programs
32	OB OmniaBio Hamilton, ON	79.5	100.0	0 insp · 2 GMP	—	0 programs
33	GS GenScript ProBio Piscataway, NJ · Nanjing, CN	79.5	100.0	—	Constrained	0 programs
34	SK SK pharmteco Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.	79.5	100.0	—	Available	0 programs
35	UM MassBiologics Boston, MA	79.0	97.2	1 insp · 0 GMP	—	0 programs
36	BB bluebird bio Manufacturing Durham, NC	78.5	—	—	—	0 programs
37	SG Syngene International Bengaluru, India	78.5	96.3	2 insp · 0 GMP	—	0 programs
38	AA Ascend Advanced Therapies London, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
39	NG NecstGen Leiden, NL	78.1	100.0	0 insp · 1 GMP	—	0 programs
40	ET Exothera Jumet, BE	78.1	100.0	0 insp · 4 GMP	—	0 programs
41	PG ProBioGen Berlin, DE	78.1	100.0	0 insp · 4 GMP	—	0 programs
42	OR Ori Biotech London, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
43	CC CCRM Toronto, ON, Canada	78.1	100.0	5 insp · 0 GMP	—	0 programs
44	CE Celonic Basel, Switzerland	78.1	100.0	0 insp · 1 GMP	—	0 programs
45	XP eXmoor Pharma Bristol, United Kingdom	78.1	100.0	0 insp · 1 GMP	—	0 programs
46	AD Advent Bioservices London, United Kingdom	78.1	100.0	0 insp · 2 GMP	—	0 programs
47	GP Green Phoenix Labs San Diego, CA	78.1	100.0	0 insp · 1 GMP	—	0 programs
48	BV Biovian Turku, Finland	78.0	99.8	1 insp · 4 GMP	—	0 programs
49	BC Biocon Biologics Bengaluru, India	77.6	97.1	4 insp · 2 GMP	—	0 programs
50	AG2 August Bioservices San Carlos, CA	77.5	98.7	1 insp · 0 GMP	—	0 programs
51	VG Viralgen Vector Core San Sebastián, Spain	76.8	100.0	0 insp · 4 GMP	Available	0 programs
52	SY Symbiosis Pharmaceutical Services Stirling, United Kingdom	76.8	100.0	1 insp · 9 GMP	—	0 programs
53	CY Cell-Easy Toulouse, FR	76.8	100.0	0 insp · 2 GMP	—	0 programs
54	CN Cellin Technologies Luxembourg, LU	76.8	100.0	0 insp · 1 GMP	—	0 programs
55	HH HiTech Health London, United Kingdom	76.8	100.0	0 insp · 9 GMP	—	0 programs
56	FH Fred Hutch Cell Therapy Lab Seattle, WA	76.3	—	—	—	454 programs
57	CG Cytiva (Mfg Services) Marlborough, MA · Uppsala, SE	74.0	—	—	—	0 programs
58	Catalent Bagsværd, Denmark (operating under Novo Holdings)	73.1	74.9	12 insp · 37 GMP	—	0 programs
59	CA Catalent (Novo Holdings) Harmans, MD · Gosselies, BE	73.1	74.9	1 insp · 0 GMP	Available	0 programs
60	LZ Lonza Biologics Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH	73.0	95.7	1 insp · 0 GMP	Limited	0 programs
61	VE Vigene Biosciences Rockville, MD	72.5	—	—	—	0 programs
62	GZ Genezen Indianapolis, IN · Lexington, MA	71.5	85.8	3 insp · 0 GMP	Available	0 programs
63	EM Emergent BioSolutions (CGT) Baltimore, MD	71.0	—	—	—	4 programs
64	IO Iovance Biotherapeutics (Mfg) Philadelphia, PA	70.8	—	—	—	31 programs
65	IU Indiana University Vector Production Facility Indianapolis, IN	66.3	—	—	—	49 programs
66	GenScript Piscataway, NJ (US HQ); Nanjing, China (primary operations)	64.0	—	—	—	0 programs
67	AN Andelyn Biosciences Columbus, OH	63.0	—	—	Available	0 programs
68	CT CTMC Houston, TX	63.0	—	—	—	0 programs
69	RA Recipharm Advanced Bio Stockholm, Sweden	63.0	—	—	—	0 programs
70	HG Hitachi Global Life Solutions (CGT) Yokohama, Japan	63.0	—	—	—	0 programs
71	SM Sumitomo Chemical Advanced Medical Tokyo, JP	63.0	—	—	—	0 programs
72	EA Esco Aster Singapore, Singapore	63.0	—	—	—	0 programs
73	AB Asklepios BioPharmaceutical (AskBio) Research Triangle, NC · San Sebastian, ES	61.8	—	—	—	10 programs
74	GF GeneFab Alameda, CA and South San Francisco	61.5	—	—	Available	0 programs
75	FB Forge Biologics Columbus, OH	61.2	—	—	Expanding	3 programs
76	Minaris (WuXi Advanced Therapies) Philadelphia, PA / Yokohama, Japan	60.5	—	—	—	0 programs
77	MA Matica Biotechnology College Station, TX	59.0	—	—	Available	0 programs
78	CL Cellares South San Francisco, CA	59.0	—	—	Available	0 programs
79	VB VintaBio Cambridge, MA	59.0	—	—	—	0 programs
80	MS Made Scientific Princeton, NJ	59.0	—	—	—	0 programs
81	WB Waisman Biomanufacturing Madison, WI	59.0	—	—	—	0 programs
82	EB ElevateBio BaseCamp Waltham, MA	59.0	—	—	—	0 programs
83	MX MaxCyte Gaithersburg, MD	59.0	—	—	—	0 programs
84	CP Cell and Gene Therapy Catapult Stevenage, United Kingdom	59.0	—	—	—	0 programs
85	C3 C3i Center Houston, TX	59.0	—	—	—	0 programs
86	EX Excellos La Rochelle, France	59.0	—	—	—	0 programs
87	CZ Cellex Cell Professionals Cologne, Germany	59.0	—	—	—	0 programs
88	AS Artis BioSolutions Lake Nona, FL	59.0	—	—	—	0 programs
89	VM Vector BioMed Cambridge, MA	59.0	—	—	—	0 programs
90	AP Applied StemCell Milpitas, CA	59.0	—	—	—	0 programs
91	AM Anemocyte Gerenzano, IT	59.0	—	—	—	0 programs
92	HX Helixmith Seoul, KR	59.0	—	—	—	0 programs
93	CTP Cell Therapies Pty Ltd Melbourne, Australia	59.0	—	—	—	0 programs
94	SS Singota Solutions Bloomington, IN	59.0	—	—	—	0 programs
95	Vantage Vector (Demo) Gaithersburg, MD	59.0	—	—	Available	0 programs
96	PO Poseida Therapeutics (CDMO) San Diego, CA	58.7	—	—	—	6 programs
97	TR Takara Bio Kusatsu, Shiga Prefecture, Japan	57.9	—	—	—	8 programs
98	TG ThermoGenesis Rancho Cordova, CA	57.8	—	—	—	1 programs
99	KC Kincell Bio Research Triangle Park, NC	56.5	—	—	—	0 programs
100	UB uBriGene Biosciences Shanghai, CN · Boston, MA	56.5	—	—	—	0 programs
101	CV CEVEC Pharmaceuticals Cologne, Germany	56.5	—	—	—	0 programs
102	CX CellGenix Freiburg, DE	56.5	—	—	—	0 programs
103	GC Green Cross Cell Yongin, KR	56.5	—	—	—	0 programs
104	CH CHA Medical & Bio Group Seongnam, KR	56.5	—	—	—	0 programs
105	IP Intas Pharmaceuticals Ahmedabad, India	51.4	45.5	0 insp · 5 GMP	—	0 programs

How we score CDMOs →

What to evaluate in a Cell & Gene Therapy CDMO

Integrated vs point-solution CDMO

Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.

Regulatory record by process class

Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.

Chain-of-identity + cold chain

Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.

Commercial track record

For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.

Which CDMOs integrate cell therapy processing with viral vector supply?

Integration matters most for ex vivo cell engineering — CAR-T and gene-modified HSC programs — where the vector and the cells need to move through a coordinated chain-of-identity. CDMOs covering both include Lonza (lentiviral + cell therapy at multiple sites), Catalent (AAV + cell therapy through the Paragon and MaSTherCell heritage), Charles River (multi-platform), and Thermo Fisher (viral vector + cell processing). The rankings above surface every CDMO tracked in either category; look for names appearing on both lentiviral and cell therapy filters as your integrated candidate shortlist.

How is cell therapy CDMO scoring different from vector CDMO scoring?

The Signal Score composition is identical, but the underlying signals diverge. Cell therapy CDMOs weight cleanroom infrastructure, chain-of-identity systems, cold-chain and cryopreservation posture, and per-patient batch process discipline. Vector CDMOs weight bioreactor scale, containment (BSL-2 for lentivirus), and analytics maturity. The Quality pillar reflects inspection history on the specific process class — a strong record on cell therapy inspections doesn't automatically de-risk vector manufacturing at the same site. Verify inspection scope at the profile level.

How CDMO Signal aggregates the cell and gene therapy view

This ranking is the union of CDMOs tagged with any viral-vector platform (AAV, lentiviral, adenoviral), any CDMO tagged directly with "gene therapy", and any CDMO tagged with "cell therapy". Each CDMO appears once regardless of how many categories they cover. This is the broadest advanced-therapy candidate list on our platform — for platform-specific filtering, use the dedicated modality pages.

What differentiates an approved-program cell and gene therapy CDMO?

CDMOs that have manufactured for approved cell or gene therapy products — Novartis/Kymriah (BMS Celgene), Gilead/Yescarta, bluebird bio's ex vivo gene therapies, Novartis Zolgensma — carry demonstrable commercial-scale posture. That level of track record is a hard buyer signal that no ranking algorithm captures perfectly; the Signal Score reflects it indirectly through inspection density and clinical footprint. For late-stage programs specifically, cross-reference the CDMO profile page with ClinicalTrials.gov and FDA product approvals for direct evidence.

Cell & Gene Therapy CDMOs — Frequently Asked Questions

Who are the top Cell & Gene Therapy CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Cell & Gene Therapy CDMOs include Bristol Myers Squibb (CGT Mfg), Novartis, City of Hope (T Cell Manufacturing). See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Cell & Gene Therapy CDMOs have FDA inspection records?

CDMO Signal tracks 31 Cell & Gene Therapy CDMOs with FDA inspection records and 333 EMA/MHRA GMP certificates across the group.

What should I look for in a cell and gene therapy CDMO?

Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.

How many cell and gene therapy CDMOs does CDMO Signal track?

109 CDMOs are tracked as cell or gene therapy manufacturers — the union of cell therapy, AAV, lentiviral, adenoviral, and gene therapy-tagged CDMOs. This is the broadest advanced-therapy candidate list on our platform.

Related modalities

Cell Therapy CDMOs AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Gene Therapy CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Viral Vector